Patrizia T.
- Country
- Italy
- Department
- Ematologia
Research Overview
Data & Insights
Has run more than one trial at 0 of 40 partner sites.
Specializations
Acute Myeloid Leukemia and Related Myeloid Disorders
The investigator’s work concentrates on Acute Myeloid Leukemia subtypes, therapy‑resistant disease, and post‑transplant residual disease.
- FLT3‑mutated AML
- NPM1‑mutated AML
- AML secondary to myeloproliferative neoplasms
- Minimal residual disease monitoring
Research integrates molecular profiling to guide intensified conditioning regimens.
Lymphoid Malignancies and Lymphoma
Focus is placed on aggressive and indolent B‑cell lymphomas as well as rare T‑cell entities.
- Diffuse Large B‑Cell Lymphoma (DLBCL)
- Mantle Cell Lymphoma
- Peripheral T‑Cell Lymphoma
- Follicular Lymphoma
Studies evaluate novel anti‑CD20 combinations and targeted kinase inhibitors.
Plasma Cell Dyscrasias
Clinical activity includes high‑risk Multiple Myeloma and precursor conditions.
- Relapsed/refractory myeloma
- High‑risk cytogenetic myeloma
- Smoldering myeloma progression
- Autologous stem‑cell transplant eligibility
Efforts target immunomodulatory agents and antibody‑drug conjugates.
Cardiovascular and Thrombotic Disorders
Investigator involvement spans Atherosclerotic cardiovascular disease and Atrial fibrillation‑related risk.
- Atherosclerotic cardiovascular disease
- Atrial fibrillation
- Venous thromboembolism prevention
- Ischemic stroke risk reduction
Trials assess anti‑inflammatory pathways and novel antithrombotic agents.
Solid Tumor Oncology
Broad engagement includes thoracic, gynecologic, and breast malignancies.
- Non‑Small Cell Lung Cancer (NSCLC)
- Triple‑Negative Breast Cancer
- Advanced ovarian cancer
- Metastatic colorectal cancer
Research evaluates checkpoint inhibition, targeted kinase blockade, and combination chemoradiation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.